Source: Journal of rheumatology. Unidade: FM
Subjects: ARTRITE REUMATOIDE JUVENIL, NEUTRÓFILOS, FÁRMACOS ANTIRREUMÁTICOS, INFECÇÕES OPORTUNISTAS
ABNT
PARDEO, Manuela et al. Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis. Journal of rheumatology, v. 46, n. 9, p. 1117-1126, 2019Tradução . . Disponível em: https://doi.org/10.3899/jrheum.180795. Acesso em: 01 nov. 2024.APA
Pardeo, M., Wang, J., Ruperto, N., Alexeeva, E., Chasnyk, V., Schneider, R., et al. (2019). Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis. Journal of rheumatology, 46( 9), 1117-1126. doi:10.3899/jrheum.180795NLM
Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz H-I, Minden K, Silva CAA da. Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis [Internet]. Journal of rheumatology. 2019 ; 46( 9): 1117-1126.[citado 2024 nov. 01 ] Available from: https://doi.org/10.3899/jrheum.180795Vancouver
Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz H-I, Minden K, Silva CAA da. Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis [Internet]. Journal of rheumatology. 2019 ; 46( 9): 1117-1126.[citado 2024 nov. 01 ] Available from: https://doi.org/10.3899/jrheum.180795